首页|期刊导航|中国肺癌杂志|黄芪桂枝五物汤治疗非小细胞肺癌软脑膜转移患者培美曲塞鞘内化疗神经毒性的随机对照研究

黄芪桂枝五物汤治疗非小细胞肺癌软脑膜转移患者培美曲塞鞘内化疗神经毒性的随机对照研究OA

Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases:A Randomized Controlled Trial

中文摘要英文摘要

背景与目的 软脑膜转移(leptomeningeal metastasis,LM)是非小细胞肺癌(non-small cell lung cancer,NSCLC)的严重并发症,培美曲塞鞘内化疗能有效延长患者生存,但较高的神经毒性发生率已成为限制其临床应用的关键因素.本研究拟探讨黄芪桂枝五物汤对NSCLC伴LM患者培美曲塞鞘内化疗神经毒性的干预效果及安全性.方法 采用前瞻性、随机、双盲、对照设计纳入220例NSCLC伴LM患者,按照随机数字表法分为治疗组(黄芪桂枝五物汤+鞘内化疗)和对照组(模拟剂+鞘内化疗),每组110例.观察两组神经毒性发生率、毒性等级、疾病控制率(disease control rate,DCR)、无进展生存期(progression-free survival,PFS)、总生存期(overall survival,OS)、生活质量及不良反应.结果 治疗组神经毒性发生率为29.1%,显著低于对照组的51.8%(P<0.001);治疗组1-2级和3-4级神经毒性发生率均低于对照组(P<0.010);神经传导检测显示:治疗组腓肠神经感觉神经动作电位波幅高于对照组(P=0.012),正中神经、尺神经传导速度呈改善趋势.治疗组DCR为76.4%,高于对照组的69.1%(P=0.045);治疗组中位PFS(7.8 vs 6.1个月,P<0.001)和OS(10.5 vs 8.9个月,P=0.007)均进一步延长.治疗组生活质量及中医证候评分改善高于对照组(P<0.05),两组不良反应发生率相当.结论 黄芪桂枝五物汤可有效降低NSCLC伴LM患者培美曲塞鞘内化疗所致神经毒性,提高化疗耐受性和生存获益,安全性良好.

Background and objective Leptomeningeal metastasis(LM)is a severe complication of non-small cell lung cancer(NSCLC).Although intrathecal Pemetrexed chemotherapy can effectively prolong patient survival,a high inci-dence of neurotoxicity has emerged as a critical factor limiting its clinical application.This study aims to investigate the efficacy and safety of Huangqi Guizhi Wuwu decoction(HGWD)in mitigating neurotoxicity induced by intrathecal Pemetrexed che-motherapy in NSCLC patients with LM.Methods In a prospective,randomized,double-blind,controlled trial,220 NSCLC patients with LM were enrolled and randomly assigned to either the treatment group(HGWD+intrathecal chemotherapy)or the control group(placebo+intrathecal chemotherapy),with 110 patients in each group.The incidence and grade of neurotox-icity,disease control rate(DCR),progression-free survival(PFS),overall survival(OS),quality of life,and adverse reactions were observed and compared between the two groups.Results The incidence of neurotoxicity in the treatment group was 29.1%,significantly lower than that in the control group(51.8%)(P<0.001).The incidences of both grade 1-2 and grade 3-4 neurotoxicity were lower in the treatment group than in the control group(P<0.010).Nerve conduction studies showed that the sensory nerve action potential amplitude of the sural nerve was significantly higher in the treatment group than in the con-trol group(P=0.012),and the conduction velocities of the median and ulnar nerves showed a trend toward improvement.The DCR was 76.4%in the treatment group,higher than 69.1%in the control group(P=0.045).Both median PFS(7.8 vs 6.1 mon,P<0.001)and median OS(10.5 vs 8.9 mon,P=0.007)were significantly prolonged in the treatment group.Improvements in quality of life and traditional Chinese medicine syndrome scores were superior in the treatment group(P<0.05).No significant difference in adverse reactions were observed.Conclusion HGWD can significantly reduce the incidence of neurotoxicity induced by Pemetrexed intrathecal chemotherapy,improve chemotherapy tolerance and survival benefits,with a good safety profile in NSCLC patients with LM.

李会颖;陈鑫;谢宇;蒋澄;林永娟;俞婷婷;尹震宇

210008 南京,南京大学医学院附属鼓楼医院老年肿瘤科南京中医药大学附属鼓楼医院老年肿瘤科210008 南京,南京大学医学院附属鼓楼医院老年肿瘤科210008 南京,南京大学医学院附属鼓楼医院老年肿瘤科210008 南京,南京大学医学院附属鼓楼医院老年肿瘤科210008 南京,南京大学医学院附属鼓楼医院老年肿瘤科210008 南京,南京大学医学院附属鼓楼医院老年肿瘤科||南京中医药大学附属鼓楼医院老年肿瘤科

肺肿瘤软脑膜转移培美曲塞神经毒性黄芪桂枝五物汤

Lung neoplasmsLeptomeningeal metastasesPemetrexedNeurotoxicityHuangqi Guizhi Wuwu decoction

《中国肺癌杂志》 2026 (2)

124-130,7

本研究受国家自然科学基金项目(No.82304567)、2025年南京市临床基础研究项目(No.202511073)、江苏省干部保健科研课题(No.BJ2408)、江苏省老龄健康科研课题(No.LKZ2023013)及南京鼓楼医院临床研究专项资金项目(No.2023-LCYJ-MS-14,No.2024-LCYJ-MS-07,No.2025-LCYJ-PY-03)资助 This study was supported by the grants from National Natural Science Foundation of China Young Scientists Fund(No.82304567,to Huiying LI),the 2025 Nanjing Municipal Clinical and Basic Research Project(No.202511073,to Zhenyu YIN),the Jiangsu Provincial Cadre Health Research Project(No.BJ2408,to Zhenyu YIN),the Jiangsu Provincial Aging and Health Research Project(No.LKZ2023013,to Zhenyu YIN),and the General Project of the Clinical Research Special Fund of Nanjing Drum Tower Hospital(No.2023-LCYJ-MS-14,to Zhenyu YINNo.2024-LCYJ-MS-07,to Yu XIENo.2025-LCYJ-PY-03,to Huiying LI).

10.3779/j.issn.1009-3419.2026.102.02

评论